AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00247052
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 100 mg per day for 14 days
Trial: NCT01349491
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
Trial: NCT00002649
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00609102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule BID
Trial: NCT00609102
Drug: n-aceylcysteine
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mgm BID
Trial: NCT00886002
Drug: Fentanyl; Buprenorphine; Naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04267926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive Placebo
Trial: NCT01075022
Drug: Colecalciferol (Vitamin D3) 300.000 UI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
Trial: NCT01075022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule, Single Dose
Trial: NCT03718065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT01843374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is to be administered as an IV solution, followed by observation.
Trial: NCT01091116
Drug: MEN16132 - 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of two high doses of MEN16132 at 2-week interval
Trial: NCT01091116
Drug: MEN16132 - 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
Trial: NCT01091116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 2 doses of Placebo control at 2-week interval
Trial: NCT00145379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04050553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00865176
Drug: Eplerenone 50 mg Tablets Sandoz Inc., USA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04450394
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04236427
Drug: Angong Niuhuang Wan Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Wan Placebo 3g
Trial: NCT04361708
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Trial: NCT04252872
Drug: HCP0605
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04252872
Drug: HGP1405
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04252872
Drug: HCP1401
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03029494
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill manufactured to mimic 1000 mg Vitamin C
Trial: NCT00817037
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily oral dosing for 6 weeks
Trial: NCT03935893
Drug: Fludarabine + Cyclophosphamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
Trial: NCT03579004
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil is used in two cycles of neoadjuvant chemotherapy
Trial: NCT04053036
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Trial: NCT02574728
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
Trial: NCT02574728
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
Trial: NCT02605837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 10 ml of placebo matched with the experimental drug.
Trial: NCT00212615
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01024517
Drug: GLPG0259 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, GLPG0259, 50 mg oral solution
Trial: NCT01024517
Drug: GLPG0259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose, GLPG0259, 50 mg solid formulation
Trial: NCT00379015
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03306914
Drug: Hydroxyethylstarch 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Hydroxyethylstarch 6% intra-operatively
Trial: NCT02275052
Drug: UMEC/VI DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
Trial: NCT02275052
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
Trial: NCT00705627
Drug: neoadjuvant chemotherapy plus concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
Trial: NCT04590274
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin
Trial: NCT00917553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellulose Placebo Capsule
Trial: NCT00907595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Trial: NCT04561960
Drug: Toothpaste Product
RxNorm normalized name: Toothpaste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
Trial: NCT00644423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00878501
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, during 4 weeks
Trial: NCT00878501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, during 4 weeks
Trial: NCT04227808
Drug: Lenvima 4 mg Oral Capsule
RxNorm normalized name: Lenvima 4 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive treatment with lenvatinib for 12 months after recruitment or until disease recurrence, intolerance AEs, or death. In case of treatment-related adverse effects, interruption or reduction is allowed.
Trial: NCT02652260
Drug: ATRIPLA^TM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
Trial: NCT00524485
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00114400
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02247726
Drug: Saline Placebo (0.5mL injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01537666
Drug: AeroVanc
RxNorm normalized name: AEROVENT PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin hydrochloride dry powder for inhalation
Trial: NCT01903356
Drug: Trajenta duo
RxNorm normalized name: Effaclar Duo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin and Metformin
Trial: NCT01527149
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01527149
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01527149
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03036891
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
Trial: NCT02723955
Drug: GSK3174998
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02610296
Drug: QPI-1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT02723955
Drug: Fluorouracil (5-FU) plus carboplatin or cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00521950
Drug: azathioprine (AZA) or 6-mercaptopurine (6-MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Trial: NCT02249377
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid
Trial: NCT00372944
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT04293081
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
Trial: NCT01326481
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT01460212
Drug: SSRI antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Trial: NCT02935010
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic for H. pylori eradication
Trial: NCT03955211
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg
Trial: NCT03955211
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT03955211
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg
Trial: NCT03955211
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 975 mg to 1 g
Trial: NCT01985152
Drug: Azilsartan Trimethylethanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01985152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01524094
Drug: Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
Trial: NCT02256150
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01397097
Drug: LNG-IUS (BAY 86-5028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
Trial: NCT02950051
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
Trial: NCT02359942
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Giving the citric acid (4g) solving in 200 ml of water before UBT
Trial: NCT03687957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Given by intramuscular injection
Trial: NCT03974854
Drug: XELOXIRI-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy with XELOXIRI-3 regimen
Trial: NCT02690506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01200758
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
Trial: NCT01200758
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
Trial: NCT04460651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Trial: NCT04205240
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03033290
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT02798159
Drug: TD0025
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03359538
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Trial: NCT00004688
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037843
Drug: I-131 Iodocholesterol
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03480360
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
Trial: NCT00325897
Drug: Macrolide Antibiotic (Azithromycin)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (daily capsule, 250 mg for 12 months)
Trial: NCT00325897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken on a daily basis
Trial: NCT04163562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
Trial: NCT02365961
Drug: ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02365961
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02365961
Drug: Noropin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01756482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00066716
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
Trial: NCT04619680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Trial: NCT02325934
Drug: Stribild, crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed Stribild tablet
Trial: NCT01003301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Trial: NCT04435925
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
Trial: NCT04435925
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
Trial: NCT02663492
Drug: Sanguisorba officinalis L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
Trial: NCT00567580
Drug: AA
RxNorm normalized name: UAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiandrogen (AA) therapy can be either 250 mg flutamide by mouth three times a day or 50 mg bicalutamide by mouth once a day.
Trial: NCT00567580
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonist can be any analog approved by the FDA (or by Health Canada for Canadian institutions) and may be given in any possible combination such that the total LHRH treatment time is 4-6 months. LHRH analogs are administered with a variety of techniques, including subcutaneous insertion of a solid plug in the abdominal wall, intramuscular injection, and subcutaneous injection.
Trial: NCT04662385
Drug: Colgate Total
RxNorm normalized name: Colgate Total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitening toothpaste that removes and prevents new stains Fights bacteria on teeth, tongue, cheeks and gums for whole mouth healthy Mint toothpaste for long lasting fresh breath Helps prevent plaque, tartar, cavities \& gingivitis
Trial: NCT02516696
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle.
Trial: NCT04094597
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebp is given in 2 ml saline
Trial: NCT04877626
Drug: Artemeter plus lumefantrina vs artesunato plus amodiquina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 received the combination AQ+AS (COARSUCAM®) which was administered orally at an initial dose of 2 tablets (200 mg AQ/540 mg AS) followed by 2 additional doses of 2 tablets at 24 and 48 hours (6 tablets in 48 hours).~Group 2 received the combination Artemeter+lumefantrina (COARTEM®) administered orally at an initial dose of 4 tablets (80 mg artemeter/480 mg lumefantrina) followed by 5 additional doses of 4 tablets at 8, 24, 36, 48, and 60 hours (24 tablets in 60 hours)
Trial: NCT01451606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To serve as placebo for duloxetine. Administration schedule same as for active drug.
Trial: NCT02718898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00039104
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV